Latest News About - complementary theraphy devices

 
Show/hide duplicate news articles.
Filter by countryfromabout
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Thursday, February 25, 2021

8:18:00 AM CET

Subscribe
RSS | MAP

Language Selection

For any category/filter, users can choose:

  1. the language of the categorized news items (e.g. fr and de to display only those news items in French and German)
  2. the language of the user interface (e.g. it for Italian)

In Top Stories, the user can display the largest clusters of news items for one language only (e.g. en shows all clusters in English)

Country Selection

Users can choose:

  1. country mentioned in the news item (articles about a country)
  2. country in which the news item was published (articles from a country)

Languages Collapse menu...Expand menu...Open help...

Select your languages

ab
ar
az
be
bg
bs
ca
cs
da
de
el
en
eo
es
et
fa
fi
fr
ga
gl
ha
he
hi
hr
hu
hy
id
is
it
ja
ka
km
ko
ku
ky
lb
lo
lt
lv
mk
ml
mn
ms
mt
my
ne
nl
no
os
pap
pl
ps
pt
ro
ru
se
si
sk
sl
so
sq
sr
sv
sw
ta
th
tr
uk
ur
vi
zh
all
Show additional languagesHide additional languages

Interface:

Quotes... Extracted quotes

Alastair Macdonald said (about John Illingworth): “The patient-focused solutions provided by Illingworth Research have never been more relevant as healthcare continues to move closer to the patient. COVID-19 has accelerated this need, benefiting patients who can continue to participate in trials from their homes and sponsors seeking new options built to boost enrollment rates,” External link

4-traders Friday, December 18, 2020 3:16:00 PM CET

John Illingworth said: “Joining Syneos Health offers significant opportunities to utilize our in-home clinical research expertise at greater scale, with the goal of enabling more patients to participate in trials,” External link

4-traders Friday, December 18, 2020 3:16:00 PM CET

James E Brown said: "It has been a pleasure working with the highly motivated and talented LACTEL team. We have confidence that Evonik will apply its resources and commitment to excellence to enable the LACTEL product line and supporting team members to thrive," External link

4-traders Monday, December 7, 2020 5:24:00 PM CET

Johann Caspar Gammelin says: "The acquisition of the LACTEL business will strengthen both our innovation growth field Healthcare Solutions and Evonik's position as a globally leading CDMO for drug delivery solutions," External link

4-traders Monday, December 7, 2020 5:24:00 PM CET

Michael Bozik said: “Knopp is excited to enter 2021 well-positioned to complete our Phase 2 dexpramipexole asthma trial and to initiate IND-enabling studies and Phase 1 trials of KB-3061,” External link

4-traders Wednesday, November 11, 2020 12:15:00 PM CET

David M Reese said: “The outcomes observed in GALACTIC-HF further the understanding of treating heart failure, a devastating disease in which half of heart failure patients will die within five years of initial hospitalization,” External link

4-traders Thursday, October 8, 2020 2:33:00 PM CEST

Claude Bertrand said: “Heart failure is a devastating condition jeopardizing patients’ lives every day. We are pleased to have collaborated with Amgen and Cytokinetics on one of the largest heart failure trials ever conducted to investigate this novel therapy in patients with heart failure. It is important to now turn our attention to fully analyzing the data from this important study in this clinical setting,” External link

4-traders Thursday, October 8, 2020 2:33:00 PM CEST

Most associated names

Daily number of articles in this category

Trend data not available for this selection.